

-- Description of the Art --

Page 2, before line 1, insert, as centered text:

-- SUMMARY OF INVENTION --;

between lines 9 and 10, insert:

-- BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the dose-dependent effect of paclitaxel and docetaxel on cell viability in hepatoma cell lines (Hep G2, Hep 3B, HA22T/VGH, and Hepa 1-6).

Figure 2 shows that 1 μ M paclitaxel-treated Hep G2 cells for 24 hours resulted in a G2/M phase arrest.

Figure 3 shows that paclitaxel (0.1 and 1 μ M) treatment induced DNA fragmentation in Hep G2 cells.

DETAILED DESCRIPTION OF THE INVENTION --

IN THE CLAIMS:

Please cancel claims 1-5 without prejudice to, or disclaimer of, the subject matter contained therein.

Please add new claims 6-22 as follows:

-- 6. (New) A pharmaceutical composition comprising, as an active ingredient, docetaxel in an amount of from 38 to 42 mg/ml.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com